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Accepted 5 February 2019Background: The Magmaris bioresorbable magnesium scaffold was successfully tested in in-vitro and in clinical
premarket studies. Subsequently the Magmaris postmarket program aimed to review intraprocedural data of
at least 2000 patients to assess user preferences, guideline adherence and intraprocedural performance in clinical
routine.
Methods: This international multicentre survey encompasses data from356 hospitals across 45 countries. As part
of the certification forMagmaris implantation, each hospital had to complete consecutive post-market evaluation
forms of their first 10 commercial Magmaris patients.
Results: From June 2016 to May 2018, data on 2018 implantations were collected. Main reasons for selecting
Magmariswas patients' life expectancy (67%, n=1359) and lowor not calcified lesions, (67%, n=1357).Magmaris
was successfully deployed in 99% of cases (n = 1995), predilatation was performed in 95% (n = 1922) and post-
dilatation in 87% (n = 1756). Physicians rated the overall performance and the pushability as good or very good
in 96% of cases (n = 1799). Guide wire friction, trackability, and conformability were rated as good or very good
in 94% of cases, and crossability in 93%. Themajority of patients were scheduled to receive dual antiplatelet therapy
for up to 12 months.
Conclusion: Generally, implantation guidelines were adhered to and theoretical advantages of the metal scaffold
observed in in-vitro tests have translated into practice with good intraprocedural performance outcomes,
confirming the controlled roll-out of this novel technology into clinical practice.
Summary for annotated table of content: The Magmaris 2000 program includes the first commercial cases at each
hospital. Overall, data on 2018 implantations were collected. The high rate of pre- and post-dilatation as well as
other parameters confirm that generally the implantation guidelines are adhered to and the good intraprocedural
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Bioresorbable scaffolds (BRS) have been developed to provide
temporary vessel support, to dissolve thereafter, and thus to overcome
long-term events associated with permanent drug-eluting stents.
However, the initial enthusiasm has been tempered due to elevated
scaffold thrombosis rates prior to bioresorption in polymeric BRS raising
corresponding safety concerns [1,2].the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
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IVUS OCT FFR Others More than one No imaging
Fig. 2. Use of additional imaging techniques and functional flow reserve. FFR-functional
flow reserve, IVUS-intravascular ultrasound, OCT-optical coherence tomography.
1141A. Wlodarczak et al. / Cardiovascular Revascularization Medicine 20 (2019) 1140–1145In contrast to polymeric scaffolds, the Magmaris sirolimus-eluting
metal BRS (Biotronik AG, Bülach, Switzerland) is made of magnesium. It
is the first clinically proven metal scaffold and has gained CE-
certification in June 2016. Premarket studies such as BIOSOLVE-II and
-III showed good safety and performance data with absence of definite
or probable scaffold thrombosis [3,4], but post-market data are scarce.
In particular, data are lacking to validate if the theoretical advantages of
metal scaffolds over polymeric scaffolds seen in in-vitro tests [5] can be
confirmed in clinical practice.
The Magnesium 2000 post-market evaluation was initiated to review
intraprocedural performance in practice, to observe user preferences, to
monitor compliance to implantation guidelines such as the “4Ps” (proper
patient and lesion selection, proper sizing, predilatation and post-
dilatation) [4,6], and hence to monitor a controlled roll-out of this novel
device into clinical routine.2. Materials and methods
2.1. Study design and population
This international multicentre survey planned to collected data from
at least 2000 consecutiveMagmaris implantations startingwith the first
commercial implantations in June 2016. As part of the certification pro-
cess to use Magmaris, physicians needed to complete a post-market
evaluation form for at least 10 cases.
There was no restriction in data collection through in- or exclusion























Fig. 1. Rationale for selecting Magmarisforms and were not monitored. Evaluated were questions related pa-
tient selection, sizing, pre- and post-dilatation, scaffold implantation,
performance outcomes and planned dual antiplatelet (DAPT) use.2.2. Device and procedure
Magmaris has been described previously [3,4]. It is a magnesium
bioresorbable scaffold coated with BIOlute consisting of sirolimus
embedded in a PLLA polymer that provides a controlled drug release
up to 90 days; the scaffold absorption time is approximately 12months.
Magmaris is available in diameters of 3.0 and 3.5 mm and lengths of
15, 20, and 25mm. Starting in early 2017, implantation guidelines were
updated to the “4P-guidelines”- Patient selection (de novo lesions with
a reference vessel diameter and lesion length closely matching the
available Magmaris sizes), Proper sizing (Magmaris should not be im-
planted in vessels b2.7 mm or N3.7 mm, if uncertain, quantitative lesion
evaluation with quantitative coronary angiography, intravascular ultra-
sound, and/or optical coherence tomography should be performed,
keeping in mind that angiograms generally underestimate the vessel
diameter by 0.25 mm), Pre-dilatation (mandatory, with a non-compliant
balloon with a 1:1 balloon to artery ratio, residual stenosis should be
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1142 A. Wlodarczak et al. / Cardiovascular Revascularization Medicine 20 (2019) 1140–1145scoring balloons may be used), and post-dilatation (post-dilatation
with a non-compliant balloon which is 0.5 mm larger than the im-
planted scaffold at high pressure N16 mm is recommended, but the
expansion limit of Magmaris of 0.6 mm should be considered; optical
coherence tomography is helpful to assess malappositions during the
learning phase).
2.3. Statistical analysis
The analysis is based on the intention-to-treat population, defined as
patients in whom the scaffold entered the guiding catheter. Further,
data analysis is based on the data available. Categorical data were calcu-
lated using absolute and relative frequencies. Statistical analyses were































































Fig. 3. Case example. (A) Angiographic assessment. A. Baseline lesion B. Predilatationwith a scor
10 atm, E. Angiography post-implantation. F. Post-dilatation with a noncompliant balloon, 3,2
tomography (OCT) 2D post-implantation: excellent strut apposition with some struts coverin
covering the side branch being resorbed.3. Results
From June 2016untilMay 2018, 651physicians in 356hospitals across
45 countries in Europe, Asia, South America, Africa and Australia/New
Zealand evaluated 2018 Magmaris implantations (Table 1). Of the 2018
implantations, approximately half (n = 1070) were conducted prior to
the introduction of the “4P” guidelines.
The rationale to useMagmariswas patient's life expectancy of N5 years
in 67% (n = 1359), low or not calcified lesions in 67% (n = 1357) and
patient's preference for resorbable technologies in 13% (n=262) (Fig. 1).
Additional imaging and functional flow reserve were used in 41%
of cases (n = 837), out of which optical coherence tomography (OCT)
was the preferred method (Fig. 2). Access was predominantly radial






ing balloon, 3,5 × 15mm, at 10 atm, C. Residual stenosis b20%. D.Magmaris, 3.5 × 25mm, at
5 × 15mm, at 20 atm, G. Post-procedure: H: 12-month follow-up. (B) Optical coherence












Second pre-dilatation performed, n = 1922 551/29%



















Magmaris sizes, n = 1934
3.0 × 15 mm 351/18%
3.0 × 20 mm 380/20%
3.0 × 25 mm 322/17%
3.5 × 15 mm 299/16%
3.5 × 20 mm 303/16%
3.5 × 25 mm 279/14%












Magmaris successfully deployed 1995/99%
Post-dilatation
Post-dilatation performed 1756/82%













Data are presented as n/%.
a e.g. Non-compliant plus scoring balloon.
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cases (n = 1922) without clear preference using a non-compliant or
compliant balloon, and a second pre-dilatation was needed in 29%
(551/1922). Magmaris was successfully deployed in 99% of patients
(n = 1995); unsuccessful deployment was mainly due to difficulties
to cross the lesion. Post-dilatation was performed in 87% (n = 1756)
with a maximum pressure above 16 atm applied in 54% of recorded
cases (921/1709) (Table 2). A case example is shown in Fig. 3 with an-
giographic and Optical Frequency Domain Imaging provided as Supple-
mentary material.
Physicians' feedback on the performance of Magmaris is provided in
Fig. 4. The performance of Magmaris was rated as good or very good in
96% of cases (n = 1799). Compared to the Absorb scaffold (Abbott
Vascular, Santa Ana, CA, USA), the conformability of Magmaris was
rated as better in 73% of cases, the crossability in 77%, the trackability
in 74% and the pushability in 74%.
The majority of patients was planned to receive DAPT for up to
12 months (Fig. 5).
4. Discussion
The main findings of the Magmaris 2000 program were (a) in
general, physicians adhered to the implantation guidelines (“4 Ps”)
even though these were not available in the current form at the
start of the data collection and (b) the Magmaris metal scaffold
showed superior intraprocedural performance outcomes compared
to a polymeric scaffold, confirming results from preclinical bench
testing.
4.1. Implantation guidelines - 4Ps
For BRS, adherence to implantation guidelines is paramount and
results in significantly better outcomes [7]. In our series, guidelines
were in general respected which resulted in 99% successful implanta-
tions despite inclusion of first-time users.
Patient selection: the majority of patients (67%) received
Magmaris scaffold based on their long life-expectancy and approx-
imately one third (36%) had discrete short lesions, both regarded as
criteria for an optimal patient outcome according to a recent con-
sensus paper [6].
Proper sizing: intracoronary imaging is recommended in case of
uncertainty about the vessel diameter, furthermore, OCT is helpful to
verify malapposition after scaffold implantation during the learning
phase [4,6]. Inmore than half of the patients in this series, no additional
imaging system aside of angiography was used. Considering the very
early experience, a higher usage of additional images would have been
desired, but it has to be acknowledged that there seems to be a trade-
off to the additional costs involved.
Pre-dilatation should be performed in all patients with a non-
compliant balloon to achieve a residual stenosis b20%. In our series,
pre-dilatation was performed in 95% of implantations and a second
predilatation in 29%, which is indicative that pre-dilatation was per-
formed thoroughly. While a non-compliant balloon was only used
in approximately half of the first pre-dilatations, they were used more
frequently (63%) for second pre-dilatation, when also 17% scoring and
cutting balloons were used. Those are particularly helpful for fibrotic
lesions to avoid slipping of the balloon.
Post-dilatation ought to be performed with a non-compliant balloon
using an inflation pressure N16 atm unless intracoronary imaging
confirms good scaffold expansion [6]. The post-dilatation rate of 87% is
indicative that the guidelines are adhered to, yet only 54% applied a
pressure of N16 atm. The reason behind might be multifactorial. Physi-
cians might be concerned to post-dilate too aggressively and eventually
intracoronary imaging already showed good scaffold apposition with
lower pressures, or physicians were used to the recommendations for
polymeric scaffolds that recommend a post-dilatation using 14 to16 atm [2]. These concerns can be alleviated through a recent
multicentre analysis in 37 de novo lesions, inwhich OCTwas performed
before and after non-compliant balloon post-dilatation with 16 atm.
Thereby post-dilatation led to a significantly lager mean scaffold
53.0% 49.6% 50.5% 50.0% 50.0% 51.1% 50.3%
41.2% 44.8% 45.2% 42.5% 44.3% 42.1% 46.1%
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Fig. 4. Rating of intraprocedural performance. (A) Magmaris scaffold (B) Magmaris versus polymeric scaffold Per physicians' feedback. (A) Data were available for 1867 to 2000 cases,
depending on the question raised (B) comparison to Absorb, data were available for 1331 to 1450 cases, depending on the question raised. Conformability: Parameter describing the
difference in vessel curvature and angulation between pre and post-stent implantation. Crossability: Ability to cross tortuous vessels and narrow lesions. Trackability: Ability of a
system to be advanced through a curved vessel anatomy. Pushability: Functional parameter to assess the force transfer from the proximal shaft to the very distal tip of the stent system.
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area (Δ~0.75 mm2), and a lower incomplete scaffold apposition area
(0.01 ± 0.04mm2 vs. 0.17 ± 0.11mm2) without observation of strut
fractures. Only one dissection occurred after implantation and prior to
post-dilatation. These findings support the view that post-dilatation is
safe and required for optimal expansion [8].
Dual antiplatelet therapywas predominantly planned for 12 months
or less which corresponds to the suggestion of a recent state of the art
paper to apply DAPT at least until scaffold degeneration [1], which is ap-






3 months or less
6 months or less
12 months or less
18 months or less
24 months or less
more than 24 months
Total
Fig. 5. Planned dual antiplatelet therapy.4.2. Intraprocedural performance
Magnesium based metal-scaffolds have several theoretical advan-
tages. (i) they achieve a good radial strength and low recoil; (ii) magne-
sium alloy has a higher tensile strength and elongation to break
resistance compared to polymers, offering a higher compliance to the
vessel geometry and lowers the risk of scaffold fracture; (iii) they can
be implanted via a single-step inflation, and (iv) electropolishing ofmag-
nesium results in soft, round edges to improve trackability, deliverability
and flow dynamics [1,2,9,10].83.2%
100.0%
60.0% 80.0% 100.0% 120.0%
Data were available for 1504 cases.
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bench tests [5,11], but were never systematically assessed in humans.
Magmaris 2000 is the first systematic assessment of intraprocedural
performance criteria and confirmed that superior bench tests compared
to Absorb translate into improved performance parameters in humans.
In particular, the Magmaris backbone has an up to 80% reduced
bending stiffness in bench tests (means is up to 80% more flexible),
compared to the polymeric Absorb scaffold [5] and correspondingly, in
73% of cases of our series, the physician rated the conformability as
better or slightly better for Magmaris compared to Absorb. Magmaris
also required up to 40% lower lesion entry and crossing force compared
to the Absorb scaffold in bench tests [5], and correspondingly, crossability
was rated as better or slightly better in 77% in our series. Trackability is
the ability of the scaffold to be advanced through a curved vessel
anatomy. In tortuous anatomies, Magmaris required 29% less peak force
in bench tests [5], and correspondingly, in 74% of cases, the physicians
rated the overall trackability as better or slightly better. High pushability
provides good feedback to the user, enables safe cathetermaneuvers, and
an optimum pushability has a positive impact on catheter trackability.
Magmaris had 34% more force transmitted from hub to tip compared to
Absorb during bench testing [5], andwas correspondingly rated as having
a better or slightly better pushability than Absorb in 74% of cases.
The overall performance of Magmaris was rated as good or very
good in 96% of patients even though Magmaris, as other scaffolds, has
substantially thicker struts compared to modern drug-eluting stents to
which physicians are accustomed to. This rating might reflect the
general knowledge gained through polymeric scaffolds, the Magmaris
training program that prepares physicians for their first implantations,
or that the Magmaris implantation feels like that of a metallic device
and hence is more comparable to permanent drug-eluting stents than
to polymeric scaffolds.
Our analysis has several limitations. Data were not monitored and
physicians' assessmentmight have been biased through the enthusiasm
of the first use of this novel product. Data comparing Magmaris with
Absorb were missing in N25% of cases. Furthermore, no safety or long-
term data were provided. Nevertheless, this is the largest series of
Magmaris implantations to date and its strength is the assurance that
the first consecutive patients were reported.
5. Conclusions
In N2000 implantations outside of clinical trials, implantation
guidelines were generally adhered to. The implantation of Magmaris
resulted in excellent acute performance outcomes confirming the
results of bench tests comparing Magmaris to the leading polymeric
scaffold and demonstrating that Magmaris performs better in terms ofdeliverability (trackability, pushability and crossability), but also in
terms of conformability.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.carrev.2019.02.003.
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